{"name":"Centre Francois Baclesse","slug":"centre-francois-baclesse","ticker":"","exchange":"","domain":"","description":"Centre Francois Baclesse is a specialized oncology center in France, focusing on cancer treatment and research. The center is known for its advanced treatments and clinical trials, contributing significantly to the field of oncology.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"Essential oils","genericName":"Essential oils","slug":"essential-oils","indication":"Other","status":"marketed"},{"name":"ARM C : single epoietin zeta","genericName":"ARM C : single epoietin zeta","slug":"arm-c-single-epoietin-zeta","indication":"Other","status":"marketed"},{"name":"Hormonotherapy","genericName":"Hormonotherapy","slug":"hormonotherapy","indication":"Other","status":"phase_3"},{"name":"Ialuset®","genericName":"Ialuset®","slug":"ialuset","indication":"Chronic and acute wounds","status":"phase_3"},{"name":"cabozantinib and nivolumab","genericName":"cabozantinib and nivolumab","slug":"cabozantinib-and-nivolumab","indication":"Other","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"ARM A : IV iron + epoietin zeta","genericName":"ARM A : IV iron + epoietin zeta","slug":"arm-a-iv-iron-epoietin-zeta","indication":"Chemotherapy-induced anemia in cancer patients","status":"marketed"},{"name":"CHEMOTHERAPY ONLY","genericName":"CHEMOTHERAPY ONLY","slug":"chemotherapy-only","indication":"Various solid tumors and hematologic malignancies (specific indication depends on chemotherapy regimen used)","status":"phase_3"},{"name":"Systematic RAI-treatment","genericName":"Systematic RAI-treatment","slug":"systematic-rai-treatment","indication":"Thyroid cancer","status":"phase_3"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"ARM B: IV iron + epoietin zeta sequence","genericName":"ARM B: IV iron + epoietin zeta sequence","slug":"arm-b-iv-iron-epoietin-zeta-sequence","indication":"Chemotherapy-induced anemia","status":"marketed"}]}],"pipeline":[{"name":"Essential oils","genericName":"Essential oils","slug":"essential-oils","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ARM A : IV iron + epoietin zeta","genericName":"ARM A : IV iron + epoietin zeta","slug":"arm-a-iv-iron-epoietin-zeta","phase":"marketed","mechanism":"This combination therapy replenishes iron stores and stimulates red blood cell production to treat chemotherapy-induced anemia.","indications":["Chemotherapy-induced anemia in cancer patients"],"catalyst":""},{"name":"ARM B: IV iron + epoietin zeta sequence","genericName":"ARM B: IV iron + epoietin zeta sequence","slug":"arm-b-iv-iron-epoietin-zeta-sequence","phase":"marketed","mechanism":"This combination therapy replenishes iron stores and stimulates red blood cell production to treat anemia.","indications":["Chemotherapy-induced anemia","Anemia of chronic disease"],"catalyst":""},{"name":"ARM C : single epoietin zeta","genericName":"ARM C : single epoietin zeta","slug":"arm-c-single-epoietin-zeta","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CHEMOTHERAPY ONLY","genericName":"CHEMOTHERAPY ONLY","slug":"chemotherapy-only","phase":"phase_3","mechanism":"This is a general chemotherapy designation rather than a specific drug, referring to cytotoxic agents that kill rapidly dividing cancer cells.","indications":["Various solid tumors and hematologic malignancies (specific indication depends on chemotherapy regimen used)"],"catalyst":""},{"name":"Hormonotherapy","genericName":"Hormonotherapy","slug":"hormonotherapy","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ialuset®","genericName":"Ialuset®","slug":"ialuset","phase":"phase_3","mechanism":"Ialuset is a topical wound healing agent that promotes tissue repair and epithelialization through enhanced cellular proliferation and collagen deposition.","indications":["Chronic and acute wounds","Burn wounds","Surgical wounds","Ulcers"],"catalyst":""},{"name":"Systematic RAI-treatment","genericName":"Systematic RAI-treatment","slug":"systematic-rai-treatment","phase":"phase_3","mechanism":"Systematic RAI-treatment involves the use of radioactive iodine to target and destroy thyroid cancer cells.","indications":["Thyroid cancer"],"catalyst":""},{"name":"cabozantinib and nivolumab","genericName":"cabozantinib and nivolumab","slug":"cabozantinib-and-nivolumab","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2025-12-02","type":"pipeline","source":"European Medical Journal","summary":"First-Line Advances in TNBC: Datopotamab Deruxtecan and Sacituzumab Govitecan at ESMO 2025 - European Medical Journal","headline":"First-Line Advances in TNBC: Datopotamab Deruxtecan and Sacituzumab Govitecan at ESMO 2025","sentiment":"neutral"}],"patents":[],"drugCount":9,"phaseCounts":{"marketed":5,"phase_3":4},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}